insights_auto
Hvorfor har 688235 gått opp? 4,06%?
GÃ¥ mer i dybdenchevron_right
688235:SHA
BeOne Medicines AG
255,98Â CNY
arrow_upward
+4,06%(+9,99) 1Â D
16. okt., 15:00:00 GMT+8 · CNY
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 688235 …
Ã…pne
253,20Â CNY
Høy
268,18Â CNY
Lav
252,09Â CNY
Markedsverdi
290,70Â mrd.
Snittvolum
2,81Â mill.
Volum
5,69Â mill.
P/E-forhold
91,43
52 u høy
319,24Â CNY
52Â u lav
205,51Â CNY
EPS
2,80Â CNY
Antall ansatte
12k
Ã…pne
253,20Â CNY
Høy
268,18Â CNY
Lav
252,09Â CNY
Markedsverdi
290,70Â mrd.
Snittvolum
2,81Â mill.
Volum
5,69Â mill.
P/E-forhold
91,43
52 u høy
319,24Â CNY
52Â u lav
205,51Â CNY
EPS
2,80Â CNY
Antall ansatte
12k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Simply Wall Street
·
for 2 timer siden
Is BeOne Medicines (ONC) Undervalued As Earnings Estimates Jump?
MarketBeat
·
for 18 timer siden
TB Alternative Assets Ltd. Makes New $5.42 Million Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Om BeOne Medicines AG
Administrerende direktørJohn Vincent Oyler | John Vincent Oyler
Ansatte12k
Grunnlagt28. okt. 2010
Hovedkontor-
Sektor-
Nettstedbeonemedicines.com